Jazz Pharmaceuticals (NASDAQ:JAZZ)‘s stock had its “buy” rating reaffirmed by equities researchers at Wells Fargo & Co in a note issued to investors on Wednesday.
Several other research firms also recently weighed in on JAZZ. BidaskClub downgraded Jazz Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Wednesday, September 19th. Morgan Stanley downgraded Jazz Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $183.00 price objective for the company. in a research note on Wednesday, July 11th. Zacks Investment Research downgraded Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, July 16th. Leerink Swann raised their price objective on Jazz Pharmaceuticals from $200.00 to $210.00 and gave the company an “outperform” rating in a research note on Friday, August 17th. Finally, Seaport Global Securities reaffirmed a “buy” rating and issued a $207.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, August 9th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and fourteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $191.76.
Shares of JAZZ traded down $15.74 during mid-day trading on Wednesday, hitting $148.67. The company’s stock had a trading volume of 36,153 shares, compared to its average volume of 462,245. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.76 and a quick ratio of 3.62. The stock has a market capitalization of $9.85 billion, a P/E ratio of 15.55, a P/E/G ratio of 0.89 and a beta of 1.06. Jazz Pharmaceuticals has a 1-year low of $128.58 and a 1-year high of $184.00.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 EPS for the quarter, beating the consensus estimate of $3.32 by $0.26. The business had revenue of $469.37 million during the quarter, compared to analysts’ expectations of $482.64 million. Jazz Pharmaceuticals had a return on equity of 25.47% and a net margin of 24.20%. The company’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period last year, the firm earned $3.22 EPS. Research analysts anticipate that Jazz Pharmaceuticals will post 11.71 EPS for the current year.
In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,300 shares of the firm’s stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $159.45, for a total transaction of $207,285.00. Following the completion of the transaction, the chief executive officer now owns 278,615 shares of the company’s stock, valued at $44,425,161.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Matthew P. Young sold 700 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $176.05, for a total value of $123,235.00. Following the transaction, the chief financial officer now directly owns 34,168 shares of the company’s stock, valued at approximately $6,015,276.40. The disclosure for this sale can be found here. Insiders have sold 34,678 shares of company stock valued at $5,959,173 in the last three months. 3.90% of the stock is currently owned by company insiders.
A number of institutional investors have recently added to or reduced their stakes in JAZZ. JPMorgan Chase & Co. grew its position in shares of Jazz Pharmaceuticals by 3.0% in the third quarter. JPMorgan Chase & Co. now owns 1,912,173 shares of the specialty pharmaceutical company’s stock valued at $321,494,000 after purchasing an additional 56,291 shares during the period. SG Americas Securities LLC grew its position in shares of Jazz Pharmaceuticals by 300.7% in the third quarter. SG Americas Securities LLC now owns 7,949 shares of the specialty pharmaceutical company’s stock valued at $1,336,000 after purchasing an additional 5,965 shares during the period. LSV Asset Management grew its position in shares of Jazz Pharmaceuticals by 3.5% in the third quarter. LSV Asset Management now owns 298,292 shares of the specialty pharmaceutical company’s stock valued at $50,151,000 after purchasing an additional 9,956 shares during the period. Systematic Financial Management LP grew its position in shares of Jazz Pharmaceuticals by 1.0% in the third quarter. Systematic Financial Management LP now owns 143,216 shares of the specialty pharmaceutical company’s stock valued at $24,079,000 after purchasing an additional 1,368 shares during the period. Finally, Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at $8,868,000. 92.95% of the stock is owned by institutional investors.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Featured Article: Capital gains and your 401(k) or IRA
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.